ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Cost-Effectiveness Analysis of Alternative Therapies in non-primary progressive Multiple Sclerosis
Research in Social and Administrative Pharmacy
◽
10.1016/j.sapharm.2010.09.006
◽
2011
◽
Vol 7
(1)
◽
pp. e1
Keyword(s):
Multiple Sclerosis
◽
Cost Effectiveness
◽
Progressive Multiple Sclerosis
◽
Cost Effectiveness Analysis
◽
Alternative Therapies
◽
Primary Progressive Multiple Sclerosis
◽
Primary Progressive
◽
Effectiveness Analysis
Download Full-text
Related Documents
Cited By
References
Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis
The Lancet Neurology
◽
10.1016/s1474-4422(19)30190-5
◽
2019
◽
Vol 18
(8)
◽
pp. 736-747
◽
Cited By ~ 9
Author(s):
Jennifer Freeman
◽
Wendy Hendrie
◽
Louise Jarrett
◽
Annie Hawton
◽
Andrew Barton
◽
...
Keyword(s):
Multiple Sclerosis
◽
Cost Effectiveness
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Progressive Multiple Sclerosis
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
◽
Home Based
◽
Randomised Controlled
Download Full-text
PND26 DEMONSTRATING COST-EFFECTIVENESS IN PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS: CASE STUDY OF A HYPOTHETICAL EMERGING TREATMENT
Value in Health
◽
10.1016/j.jval.2020.04.919
◽
2020
◽
Vol 23
◽
pp. S263
Author(s):
N. Brighton
◽
C. Treharne
Keyword(s):
Multiple Sclerosis
◽
Cost Effectiveness
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Multiple Sclerosis Case
◽
Primary Progressive
Download Full-text
Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis
Value in Health
◽
10.1111/j.1524-4733.2004.75007.x
◽
2004
◽
Vol 7
(5)
◽
pp. 554-568
◽
Cited By ~ 44
Author(s):
Lisa A. Prosser
◽
Karen M. Kuntz
◽
Amit Bar-Or
◽
Milton C. Weinstein
Keyword(s):
Multiple Sclerosis
◽
Cost Effectiveness
◽
Glatiramer Acetate
◽
Interferon Beta
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Newly Diagnosed
◽
Primary Progressive
Download Full-text
Faculty Opinions recommendation of Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.736220378.793570470
◽
2020
◽
Author(s):
Jeremy Chataway
◽
Nevin John
Keyword(s):
Multiple Sclerosis
◽
Cost Effectiveness
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Progressive Multiple Sclerosis
◽
Cost Effectiveness Analysis
◽
Effectiveness Analysis
◽
Home Based
◽
Randomised Controlled
Download Full-text
Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios
Value in Health
◽
10.1016/j.jval.2016.03.200
◽
2016
◽
Vol 19
(3)
◽
pp. A62-A63
Author(s):
K Suh
◽
JJ Carlson
◽
LP Garrison
Keyword(s):
Multiple Sclerosis
◽
Cost Effectiveness
◽
Standard Care
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Potential Cost
◽
Primary Progressive
◽
Multiple Sclerosis Patients
Download Full-text
Searching for early CSF biomarkers of primary progressive multiple sclerosis
10.26226/morressier.5b719e465aff74008ae4cb58
◽
2018
◽
Author(s):
Damiano Marastoni
◽
Roberta Magliozzi
Keyword(s):
Multiple Sclerosis
◽
Progressive Multiple Sclerosis
◽
Csf Biomarkers
◽
Primary Progressive Multiple Sclerosis
◽
Primary Progressive
Download Full-text
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Case Medical Research
◽
10.31525/ct1-nct04035005
◽
2019
◽
Author(s):
Keyword(s):
Multiple Sclerosis
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Efficacy And Safety
◽
Primary Progressive
Download Full-text
Faculty Opinions recommendation of Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717955622.793460622
◽
2012
◽
Author(s):
Monica Marta
Keyword(s):
Multiple Sclerosis
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Primary Progressive
◽
Meningeal Inflammation
Download Full-text
Faculty Opinions recommendation of Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718018944.793478763
◽
2013
◽
Author(s):
Marco Rovaris
Keyword(s):
Multiple Sclerosis
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Disease Course
◽
Primary Progressive
Download Full-text
Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing–Remitting and Primary Progressive Multiple Sclerosis
Neuropsychology Review
◽
10.1007/s11065-021-09479-3
◽
2021
◽
Author(s):
Yuan Cao
◽
Wei Diao
◽
Fangfang Tian
◽
Feifei Zhang
◽
Laichang He
◽
...
Keyword(s):
Multiple Sclerosis
◽
Gray Matter
◽
Progressive Multiple Sclerosis
◽
Primary Progressive Multiple Sclerosis
◽
Sensorimotor Network
◽
Primary Progressive
◽
Gray Matter Atrophy
◽
Relapsing Remitting
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close